Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on August 14, 2019. The filing serves to announce the company's financial results for the three and six months ended June 30, 2019. The registrant is incorporated in California and its common stock is listed on the NYSE American.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a reference to a press release (Exhibit 99.1) which contains the detailed financial data for the periods ended June 30, 2019.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the text provided. It directs readers to the attached press release for the announcement of results for the three and six months ended June 30, 2019.
Guidance, Outlook, and Risks
The filing includes a standard forward-looking statements disclaimer. It notes that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties. The registrant disclaims any obligation to update these statements. Specific risks are referenced as being contained in the company's Form 10-K and Forms 10-Q under the heading "Risk Factors."
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2019) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and liquidity status as detailed in the referenced press release.
- Consult the most recent Form 10-K and 10-Q filings for a comprehensive list of risk factors.
- Confirm the trading status of OCX on the NYSE American.